Nikethamide250 mg/ml

Nikethamide is an older-generation respiratory and central nervous system (CNS) stimulant (analeptic agent). Its clinical use has substantially declined and it has been superseded in most modern healthcare settings by mechanical ventilation, targeted reversal agents (e.g., naloxone, flumazenil), and advanced respiratory monitoring.

Historically established uses

• Stimulation of respiration in cases of drug-induced respiratory depression, such as that caused by anesthetic agents or overdose of CNS depressants, when used under close medical supervision in a hospital setting.
• Adjunctive respiratory stimulation during recovery from anesthesia in older clinical protocols.

Current status

Nikethamide is not considered a first-line or routine therapy in contemporary practice because of its narrow margin between an effective dose and a dose that causes toxicity (including seizures). Where available, it should be reserved for use by trained medical personnel with continuous monitoring, and only when definitive respiratory support (e.g., mechanical ventilation) is not immediately available.

Each formulation of Nikethamide contains Nikethamide as the active pharmaceutical ingredient. Available strengths and formulations (e.g., injectable solution) vary by manufacturer; refer to the product label for the exact strength and excipients of the specific Nikethamide product dispensed.

Nikethamide (chemically, N,N-diethylnicotinamide) is a synthetic analeptic drug that stimulates the central nervous system, particularly the respiratory centers in the brainstem. It was historically administered by injection to stimulate breathing in patients with respiratory depression. Because of its narrow therapeutic margin and the availability of safer, more effective modern respiratory support techniques, Nikethamide is used far less frequently today and only under close medical supervision.

Nikethamide belongs to the pharmacological class of Analeptics (Respiratory and CNS Stimulants).

Nikethamide stimulates respiration primarily through direct excitatory effects on the medullary respiratory centers and, at higher doses, through stimulation of the carotid and aortic body chemoreceptors. This leads to an increase in the rate and depth of breathing. Nikethamide also has generalized, dose-dependent CNS excitatory effects; at doses above the therapeutic range these excitatory effects extend to the motor cortex and spinal cord, increasing the risk of tremor and convulsions. Its onset of action after intravenous administration is rapid, but its duration of effect is short, often necessitating repeated dosing to sustain an effect — one of the key limitations that has reduced its clinical use.

Nikethamide is administered parenterally (by intravenous or intramuscular injection) by a qualified healthcare professional. It is not intended for oral self-administration or unsupervised outpatient use. Vital signs, including heart rate, blood pressure, and neurological status, should be monitored during and after administration.

Clinically Significant Interactions

• CNS depressants (e.g., barbiturates, opioids, sedative-hypnotics): Because Nikethamide is often used specifically to counteract CNS/respiratory depression from these agents, concurrent use requires careful individualized dosing; the interaction is typically therapeutic in intent but requires close titration to avoid under- or over-stimulation.
• Other CNS stimulants or convulsant agents: Concurrent use with other agents that lower the seizure threshold (e.g., certain analeptics, high-dose local anesthetics) may additively increase the risk of seizures with Nikethamide.
• Sympathomimetic agents: Concurrent use with Nikethamide may increase the risk of hypertension and arrhythmia due to additive cardiovascular stimulation.
• Monoamine oxidase inhibitors (MAOIs): Theoretical risk of exaggerated CNS and cardiovascular stimulation when combined with Nikethamide; use with caution.

Common

• Restlessness, agitation, tremor
• Nausea, vomiting
• Flushing, sensation of warmth
• Injection-site irritation or pain

Serious (usually dose-related)

• Seizures/convulsions
• Cardiac arrhythmias
• Severe hypertension or hypertensive crisis
• Hyperventilation

Because of the narrow margin between the effective dose and the dose causing these serious effects, Nikethamide requires close clinical monitoring during use.

Data on the use of Nikethamide during pregnancy are limited. As a general precaution with agents lacking well-established safety data in pregnancy, Nikethamide should be used during pregnancy only if clearly needed and only when the potential benefit justifies the potential risk to the fetus, and only under direct medical supervision. It is not known whether Nikethamide passes into breast milk; a decision on continuing or discontinuing breastfeeding after use of Nikethamide should be made in consultation with a physician, weighing the benefits of breastfeeding against any potential risk to the infant.

Nikethamide has a narrow margin between an effective dose and a dose causing toxicity. It should be administered only by trained personnel in a setting equipped for monitoring and resuscitation. Use with caution in patients with cardiac disease, a history of seizures (see Contraindications), or hepatic/renal impairment, as these conditions may increase the risk of adverse effects. Nikethamide is not a substitute for definitive respiratory support such as mechanical ventilation and should not delay escalation to such support when clinically indicated. Elderly patients may be more sensitive to the CNS-stimulant effects of Nikethamide and should be monitored closely.

Overdose of Nikethamide can cause serious CNS and cardiovascular toxicity, including convulsions, severe agitation, cardiac arrhythmias, and hypertensive crisis. If an overdose of Nikethamide is suspected, seek immediate medical attention or contact emergency services/poison control. Management is supportive and should be carried out in a hospital setting, including seizure control and cardiovascular monitoring, as directed by the treating physician; there is no specific antidote.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not use after the expiry date printed on the pack.

• Pediatric patients: Safety and efficacy of Nikethamide have not been well established in children in modern practice; use is generally avoided in favor of safer alternatives (see Pediatric Use).
• Elderly patients: May be more sensitive to the CNS-stimulant effects of Nikethamide; use with caution and close monitoring.
• Hepatic/renal impairment: Use Nikethamide with added caution given the potential for altered clearance (see Precautions).
• Pregnancy and lactation: See Pregnancy and Lactation section.

Nikethamide is used for acute, short-term stimulation of respiration and is not intended for long-term or maintenance therapy. The duration of use is determined by the treating physician based on the patient's clinical response and resolution of the underlying respiratory depression, or until definitive respiratory support (e.g., mechanical ventilation) can be provided.

Nikethamide is classified as an Analeptic Agent, within the broader classes of Respiratory Stimulants and Central Nervous System (CNS) Stimulants.

Nikethamide acts primarily by directly stimulating the respiratory centers in the medulla oblongata and, at higher doses, by stimulating the carotid and aortic body chemoreceptors, increasing the rate and depth of respiration. This action is dose-dependent and generalizes to broader CNS excitation at higher doses, which underlies both its use as a respiratory stimulant and its risk of causing convulsions.

The safety and efficacy of Nikethamide in pediatric patients, including neonates and infants, have not been well established in current clinical practice. Historical use of Nikethamide as a respiratory stimulant in neonates has largely been abandoned in favor of safer, better-studied alternatives and modern respiratory support. If Nikethamide is considered in a pediatric patient, it should be used only under the direct supervision of a specialist physician in a monitored hospital setting, with careful attention to the increased risk of seizures in this population.